Status | Study |
Not yet recruiting |
Study Name: VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Condition: Endometrial Clear Cell Adenocarcinoma Endometrial Mixed Adenocarcinoma Date: 2017-04-14 Interventions: Procedure: Biopsy Undergo imag |
Not yet recruiting |
Study Name: Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer Condition: Grade 1 Endometrial Endometrioid Adenocarcinoma Grade 2 Endomet Date: 2017-01-11 Interventions: Drug: Entinostat Given PO |
Recruiting |
Study Name: Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid A Date: 2016-07-29 Interventions: Biological: Bevacizumab Given |
Not yet recruiting |
Study Name: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid A Date: 2016-07-20 Interventions: Drug: Atezolizumab Given IV |
Recruiting |
Study Name: Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Condition: Endometrial Endometrioid Adenocarcinoma Endometrial Mixed Adeno Date: 2016-03-30 Interventions: Drug: Copanlisib Given IV |
Recruiting |
Study Name: Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid A Date: 2016-03-15 Interventions: Drug: Carboplatin Given IV |
Recruiting |
Study Name: Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Date: 2015-07-17 Interventions: Drug: Cediranib Maleate Given |
Recruiting |
Study Name: Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Condition: Deleterious BRCA1 Gene Mutation Deleterious BRCA2 Gene Mutation Date: 2015-01-23 Interventions: Drug: Cediranib Maleate Given |
Active, not recruiting |
Study Name: The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy Condition: Grade 1 Endometrial Endometrioid Adenocarcinoma Grade 2 Endomet Date: 2014-12-22 Interventions: Drug: Depot medroxyprogesterone acetate |
Completed |
Study Name: POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus Condition: Carcinoma, Endometrioid mTOR Protein Date: 2014-02-11 Interventions: Drug: Temsirolimus Other Name: Torisel |